CovidNeuroOnc: A UK multicenter, prospective cohort study of the impact of the COVID-19 pandemic on the neuro-oncology service

Collapse authors list.
Fountain, DM, Piper, RJ, Poon, MTC, Solomou, G, Brennan, PM, Chowdhury, YA, Colombo, F, Elmoslemany, T, Ewbank, FG, Grundy, PL et al (show 56 more authors) , Hasan, MT, Hilling, M, Hutchinson, PJ, Karabatsou, K, Kolias, AG, McSorley, NJ, Millward, CP ORCID: 0000-0001-7727-1157, Phang, I, Plaha, P, Price, SJ, Rominiyi, O, Sage, W, Shumon, S, Silva, IL, Smith, SJ, Surash, S, Thomson, S, Lau, JY, Watts, C, Jenkinson, MD ORCID: 0000-0003-4587-2139, Al-Tamimi, Y, Alalade, AF, Albanese, E, Bailey, M, Brodbelt, AR, Chalmers, A, Chan, HW, Coope, DJ, Cundliffe, S, D'Urso, PI, Entwistle, H, Evans, RM, Fielding, R, Gkolemis, C, Hammerbeck-Ward, C, Jeyaretna, DS, King, AT, Laurente, RM, Leggate, J, Lewis, R, MacLean, J, McBain, C, McKenna, GS, Molloy, E, Pathmanaban, ON, Patkar, P, Powell, J, Rutherford, SA, Santarius, T, Sinha, S, Sitaraman, M, Solth, A, Thakur, B, Wadeson, A, Wykes, V and Zafar, MR (2021) CovidNeuroOnc: A UK multicenter, prospective cohort study of the impact of the COVID-19 pandemic on the neuro-oncology service .

Access the full-text of this item by clicking on the Open Access link.

Abstract

Background. The COVID-19 pandemic has profoundly affected cancer services. Our objective was to determine the effect of the COVID-19 pandemic on decision making and the resulting outcomes for patients with newly diagnosed or recurrent intracranial tumors. Methods. We performed a multicenter prospective study of all adult patients discussed in weekly neuro-oncology and skull base multidisciplinary team meetings who had a newly diagnosed or recurrent intracranial (excluding pituitary) tumor between 01 April and 31 May 2020. All patients had at least 30-day follow-up data. Descriptive statistical reporting was used. Results. There were 1357 referrals for newly diagnosed or recurrent intracranial tumors across 15 neuro-oncology centers. Of centers with all intracranial tumors, a change in initial management was reported in 8.6% of cases (n = 104/1210). Decisions to change the management plan reduced over time from a peak of 19% referrals at the start of the study to 0% by the end of the study period. Changes in management were reported in 16% (n = 75/466) of cases previously recommended for surgery and 28% of cases previously recommended for chemotherapy (n = 20/72). The reported SARS-CoV-2 infection rate was similar in surgical and non-surgical patients (2.6% vs. 2.4%, P > .9).

Item Type:	Conference Item (Unspecified)
Uncontrolled Keywords:	brain tumor, COVID-19, intracranial tumor, neurooncology, | SARS-CoV-2
Divisions:	Faculty of Health & Life Sciences Faculty of Health & Life Sciences > Inst. Population Health
Depositing User:	Symplectic Admin
Date Deposited:	21 Jul 2021 09:11
Last Modified:	28 Feb 2026 23:54
DOI:	10.1093/noajnl/vdab014
Open Access URL:	https://doi.org/10.1093/noajnl/vdab014
Related Websites:	Author
URI:	https://livrepository.liverpool.ac.uk/id/eprint/3130804
Disclaimer:	The University of Liverpool is not responsible for content contained on other websites from links within repository metadata. Please contact us if you notice anything that appears incorrect or inappropriate.